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OBJECTIVES: To investigate the phenomenon of PPI switching in the acid related 
disorders treatment in an Italian primary care setting during 2005–2008 (before and 
after PPIs’ patents expired) and to estimate the costs of health care resources consump-
tion associated with this phenomenon. METHODS: Retrospective cohort study was 
performed analyzing data from 127 GPs of Naples in the south of Italy. PPI users for 
ARD treatment within each study year were selected from source population. Switch-
ers were deﬁ ned patients changing from one PPI to another within each study year. 
Multivariate logistic regressions were used to assess the potential predictors of PPI 
switching and to investigate the factors inﬂ uencing the direction of the switch. Cost 
was expressed as Euro 2008 per PPI user. RESULTS: The phenomenon of PPI switch-
ing rose from 13.0% in 2005 to 16.7% in 2008 with a peak of 18.8% in 2006. 
Calendar years, long-term treatments and GERD diagnosis were positive predictors 
of PPI switching. All years analyzed (versus 2005) were associated with switching to 
lansoprazole while the 2008 year was strongly associated with switching to omepra-
zole and pantoprazole. Very long-term treatment (>11 pack/years) group accounted 
for 66.3% of the total primary care cost. Switchers increased primary care costs by 
c61.1 compared with no switchers, reaching an incremental cost of c133.1 per user-
year in the case with more than 1 switch. CONCLUSIONS: In Italy the launch of 
generic PPIs in the national market generates the increasing amount of chronic treat-
ments and therapeutic substitution that will probably have had a negative impact on 
the total savings on PPIs, achievable by the introduction of generic products. Policy 
rules favouring generic PPIs prescribing can often inﬂ uence physicians’ decision to 
select the appropriate treatment for each patient.
PGI30
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OBJECTIVES: The generic drug market within the statutory health insurance (SHI) 
in Germany is affected by price regulations like ﬁ xed amounts or rebats. Legal amend-
ments led to an increasing importance of price discounts with uncertain impact on 
pharmaceutical supply of the patients. To assure a justiﬁ able price for the pharma-
ceutical companies and high quality a model has been developed by the Federal 
Association of Medicines Manufacturers e. V. (BAH) for the regulation of reimburse-
ment prices, e.g. cost-beneﬁ t based price corridors. Aim of the study is to test the 
described methods for feasibility. METHODS: The prior published methods for the 
development of reimbursement price corridors are applied and tested for feasibility by 
use of the indication Gastroesophageal Reﬂ ux Disease (GERD). The methods intend 
the derivation of one or more corridors following a deﬁ ned decision algorithm based 
on primary and secondary beneﬁ t criteria. Therefore a systematic assessment of ben-
eﬁ ts of proton pump inhibitors (PPIs), H2-Blockers and sucralfat is the foundation of 
further decisions concerning the number of corridors to consider. Several methodical 
approaches for the deﬁ nition of height of each corridor are tested. RESULTS: PPIs 
are more effective than H2-Blocker or sucralfat concerning primary beneﬁ t endpoints. 
The assessment is based on secondary literature for ﬁ nancial and time reasons that 
will be relevant when implementing the model in real decision problems, too. Based 
on the results of the beneﬁ t assessment two corridors were implemented into the 
model. The height of each corridor can be derivated by use of angles as well as by 
other mathematical parameters like mean, quartiles etc. Both approaches show speciﬁ c 
limitations. CONCLUSIONS: The feasibility of the reported concept can be shown. 
Several limitations, e.g. assessment of beneﬁ ts based on secondary literature should 
be considered. Use of angles or mathematical parameter should be discussed with 
decision makers before implementation.
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EVALUATING THE POST OPERATIVE PRESCRIBING PRACTICES FOR 
APPENDICITIS IN PUBLIC HEALTH FACILITIES IN PAKISTAN
Malik M, Hussain A, Abassi N, Khan J
Hamdard University, Islamabad, Punjab, Pakistan
OBJECTIVES: To investigate the pattern of prescribing practices for postoperative 
appendicitis in public health facilities. METHODS: The study population consisted 
of the largest public hospital Federal Government Services Hospital (Polyclinic) from 
Punjab, Pakistan; Islamabad. a sample of 100 prescriptions of post operative appen-
dicitis was collected from the public hospital. RESULTS: A total of 13.3% prescrip-
tions out of 100 contain 2 drugs, 40% contains 3 drugs, 40 % contains 4 drugs & 
6.7% contains 5 dugs. Only 6.7% prescriptions contain drugs prescribed by generic 
while 93.3% prescriptions were not prescribed by generic name. a total of 3.3% 
prescriptions contain no antibiotics, 76.6% prescriptions contain 1 antibiotic, while 
20% prescriptions contain 2 antibiotics. On the other hand 23.3% prescription does 
not contain any injection, 10% prescriptions contain 2 injections, 23.3% prescriptions 
contain 3 injections, while 43.3% prescriptions contain 4 injections. One hundred 
percent of prescribers suggested that standard treatment guidelines and essential drug 
list should be available and updated regularly in hospital and must be strictly followed. 
a total of 33.3% of prescribers think the essential drug list should be properly regu-
lated and updated should by the hospital management, 33.3% prescribers think by 
Ministry of Health while 33.3% prescribers thinks it is the duty of Hospital pharma-
cist. This difference was noted with respect to age of the prescriber (p = 0.020) in the 
prescribing practice of physicians in the public health facility. CONCLUSIONS: The 
major reasons for irrational drug use in case of post operative appendicitis were due 
to polypharmacy, overuse of antibiotics and injection and lack of standard treatment 
guidelines in the hospital. Thus the extent of irrational drug use in the public sector 
calls for in-depth investigation of the system factors and motivations that underlying 
these problems in the practice and the development of interventions that target the 
causative factors of inappropriate prescribing practice in Pakistan. 
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USING DATA ENVELOPMENT ANALYSIS TO ESTABLISH THE 
EFFECTIVENESS EVALUATION OF DRUGS
Wu ML
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OBJECTIVES: The development and research in pharmaceutical industry has con-
stantly created new listing drugs which provide more therapeutic effect and lower 
side-effects than former drugs, but the price become more expensive relatively. In order 
to balance the trade-off between medical quality and cost reduction, hospitals have 
to make the decision-making between the former drugs and the new listing drugs, 
which have similar therapeutic effectiveness. In this regard, the most primary issue in 
this research to solve is to establish a more objective and efﬁ cient decision-making 
analysis that consider both effectiveness and cost for the drugs which have the similar 
therapeutic effect. METHODS: We use data envelopment analysis (DEA) to solve this 
problem, We screen six critical factors, daily drug expenses, drug proﬁ ts, side-effect, 
consumption, patent duration and lead time. Evaluation of relative efﬁ ciency of the 
option with DEA method must be built on the relative performance data of every 
input or output attributes of each decision-making unit. RESULTS: This study uses 
four kinds of proton pump inhibitors (PPI) for effectiveness evaluation (the code A, 
B, C, D drugs to replace its original name), ﬁ rst according to deﬁ nition of the factors 
to collect relevant data. We use the DEA method to treat these data, Drug a in the 
DEA method analysis results is the most effective (6.6542E-06), Drug D is the second 
(4.2381E-06), Drug B is the third (2.1165E-06) and Drug C is the worst (1.2786E-06). 
CONCLUSIONS: Through this research model, we transfer complex decision-making 
goals into various measurable or comparable factors that can compare the relative 
importance. The evaluation result may not let all decision-makers and users to adopt 
at all. But it is more comprehensive and objective to evaluate the effectiveness of 
decision-making models than that in the past. 
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EMERGENCY CONTRACEPTION FOR UNINTENDED PREGNANCY: ROLE 
OF ULIPRISTAL, A NOVEL PROGESTERONE RECEPTOR MODULATOR
Aggarwal A
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OBJECTIVES: Unintended pregnancies represent a global health problem with over 
80 million annual pregnancies. These are associated with an increased risk of morbid-
ity and a considerable impact on women’s quality-of-life. Globally, 38% of all preg-
nancies are unintended resulting in 42 million induced abortions and 34 million 
unintended births. This corresponds to 43% of all child-births worldwide. a novel 
drug “Ulipristal” was introduced in Europe in May 2009 with efﬁ cacy beyond 72 
hours after unprotected coitus. The objective of this review was to determine the safety 
and efﬁ cacy proﬁ le of ulipristal compared to levonorgestrel. METHODS: A number 
of databases (PUBMED, EMBASE, POPLINE, CENTRAL and clinicaltrials.gov) were 
searched and the citations screened to identify randomised controlled trials (RCTs) 
reporting efﬁ cacy and safety outcomes of ulipristal. Grey literature was searched to 
identify the cost associated with unintended pregnancies. Summary-statistics (Ran-
dom-Effects: DerSimonian-Laird) were used to assess pregnancy and adverse-events 
outcomes. RESULTS: Seven RCTs were identiﬁ ed and only two reported pregnancy 
outcomes. In a pooled analyses when compared to levonorgestrel, ulipristal showed 
better efﬁ cacy results in preventing pregnancy following unprotected coitus on day 1 
and day 3 (Day 1, RR = 0.435, [95%CI:0.148, 1.279] and Day 3, RR = 0.376, 
[95%CI:0.110, 1.283]). However, these results were non-signiﬁ cant. Conversely, sub-
group analysis showed that if administered on day 2, this trend was reversed with 
administration of levonorgestrel being associated with fewer pregnancies (RR = 1.309, 
[95%CI: 0.572, 2.996]). The frequency of adverse events like nausea, headache, 
fatigue and dizziness was similar with both the drugs. Unintended pregnancies were 
found to be associated with huge costs that amounted up to US$ 5 billion in US during 
